|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01681 CONSUN PHARMA
Nominal 
8.620 +0.350 (+4.232%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 2,590,115 | 10.705% | 2,339,650 | 2,044,660 | 1,752,830 | 1,728,256 |
| Cost of Sales | (668,437) | 15.900% | (576,738) | (517,324) | (431,159) | (466,851) |
| Gross Profit | 1,921,678 | 9.006% | 1,762,912 | 1,527,336 | 1,321,671 | 1,261,405 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | (326,136) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 863,703 | 15.717% | 746,393 | 695,861 | 583,736 | 133,663 | |
| Taxation | (77,149) | 23.053% | (62,696) | (108,744) | (101,993) | (70,541) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,020) | 155.696% | (790) | 3,055 | 17,045 | 16,698 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 784,534 | 14.882% | 682,907 | 590,172 | 498,788 | 79,820 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (47,653) | 14.879% | (41,481) | (26,343) | (6,487) | 12,292 |
| Depreciation & Amortisation | 78,089 | 2.271% | 76,355 | 72,989 | 71,795 | 73,115 |
| Directors' Emoluments | 41,942 | 6.720% | 39,301 | 37,542 | 28,346 | 32,543 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 99.000 | 15.116% | 86.000 | 74.000 | 61.000 | 9.000 |
| DPS (cts) | 40.809 | -- | 26.265 | 24.361 | 23.449 | 18.022 |
| Dividend Payout Ratio (%) | 41.221% | -- | 30.541% | 32.920% | 38.440% | 200.240% |
| Cash flow per share ($) | 1.035 | -- | 1.199 | 0.905 | 1.061 | 0.452 |
| NBV per share ($) | 4.472 | -- | 3.897 | 3.176 | 2.709 | 2.304 |
| Remarks: | Real time quote last updated: 01/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 399,765 |
| %Change | 14.910% |
| EPS / (LPS) | RMB 0.499 |
| NBV Per Share (¥) | RMB 4.383 |